Fennec Pharmaceuticals

Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Fennec Pharmaceuticals reports Q1 loss, sees growth in new therapies

Fennec Pharmaceuticals' Q1 2023 earnings call highlighted a mix of financial results, market strategies, and analyst inquiries. Despite challenges in achieving profitability, the company showcased strengths in product launches and market acceptance. Opportunities for growth through expanded adoption, market strategies, and R&D investments were discussed.

Fennec Pharmaceuticals reports robust revenue growth and strategic milestones in Q2 2023

Fennec Pharmaceuticals demonstrated strong revenue growth and key regulatory milestones in Q2 2023, positioning the company for future success.
While facing financial challenges and operational inquiries, Fennec's strategic focus on commercial expansion and patient support programs remains a key strength.
With a solid cash position and experienced leadership, Fennec is well-positioned to capitalize on market opportunities and drive further growth in the oncology sector.

Fennec Pharmaceuticals excels in Q3 with PEDMARK growth strategies

Fennec Pharmaceuticals demonstrated robust financial performance and strategic market positioning in Q3 2023, leveraging the successful launch of PEDMARK in the U.S. and plans for European expansion.
While facing challenges in metrics tracking, manufacturing transitions, and pipeline prioritization, the company remains focused on maximizing PEDMARK's market potential and competitive edge.
Opportunities lie in expanding market presence in Europe, negotiating favorable pricing strategies, and solidifying PEDMARK's position as a key therapy alongside cisplatin.

Fennec Pharmaceuticals excels in Q4 2023, secures strategic partnerships

Fennec Pharmaceuticals delivered strong financial results and strategic advancements in Q4 2023, positioning the company for growth.
While facing challenges in increased expenses and access barriers, Fennec's focus on pediatric oncology and strategic partnerships offer promising opportunities.
With a solid financial foundation and market endorsements, Fennec is well-positioned to capitalize on its growth potential and expand its market presence.

Fennec Pharmaceuticals reports solid Q1 performance amidst market challenges

Fennec Pharmaceuticals navigated challenges in Q1 2024 while maintaining strong financial performance and strategic advancements. The company's focus on resolving issues, expanding market reach, and optimizing sales strategies positions it for future success.

Fennec Pharmaceuticals reports solid Q2 performance, eyes market expansion

Fennec Pharmaceuticals' Q2 2024 performance reflects progress in PEDMARK's commercialization and market access.
While facing challenges in specific business segments, the company's strong financial position and strategic partnerships are notable strengths.
Opportunities lie in targeted market expansion and clear communication of growth strategies to investors.

Fennec Pharmaceuticals reports robust Q3 performance and eyes international expansion

Fennec Pharmaceuticals showcased solid financial performance in Q3 2024, with a strong focus on the AYA market.
The company's strategic imperatives for PEDMARK and leadership enhancements position it for future growth.
While challenges exist in increasing awareness and managing expenses, opportunities in revenue growth and market expansion are promising.

Fennec Pharmaceuticals reports strong Q4 sales and global expansion

Fennec Pharmaceuticals demonstrated solid financial performance and market progress in Q4 2024. Strategic partnerships, successful product launches, and a strong balance sheet position the company for future growth. Challenges in trial results evaluation and strategic focus areas require attention for sustained success.

Fennec Pharmaceuticals reports robust Q1 performance and eyes global expansion

Fennec Pharmaceuticals delivered a strong performance in Q1 2025, with notable growth in net product sales and effective cost management. The company's strengths lie in its operational execution, financial stability, and resilience against potential tariff impacts. While facing challenges in sustaining growth and optimizing expenses, Fennec has opportunities for global expansion and strategic partnerships.

Fennec Pharmaceuticals reports robust Q2 growth, eyes EU and Japan

Fennec Pharmaceuticals demonstrated strong revenue growth and market acceptance for PEDMARK in Q2 2025, with a focus on profitability in the near future. While facing challenges in managing expenses and regulatory compliance, the company's strategic strengths lie in product endorsements and market expansion. Opportunities in expanding market reach, particularly in the EU and Japan, present avenues for sustained growth and establishing PEDMARK as a standard of care.

Fennec Pharmaceuticals reports record sales and secures market exclusivity

Fennec Pharmaceuticals delivered strong financial performance in 2025, with record sales and disciplined financial decisions. The company made significant strides in clinical evidence strategy and market exclusivity for PEDMARK. While challenges exist, Fennec is well-positioned for growth with anticipated positive cash flow and strategic partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.